FIELD: medicine.
SUBSTANCE: present group of inventions refers to medicine, namely, to therapy, and concerns the treatment of neutropenia. To this end, an effective amount of a retinoid agonist of tamibarotene is administered.
EFFECT: this provides an effective treatment of neutropenia due to induction of neutrophil differentiation, as well as an increase in immunity due to stimulation of GSK granulopoiesis.
9 cl, 4 ex, 8 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHORBOL ESTER COMPOSITIONS AND METHODS OF USING THEM FOR TREATING OR REDUCING DURATION OF CYTOPENIA | 2015 |
|
RU2730998C2 |
| NEUTROPENIA REDUCTION METHOD | 2018 |
|
RU2790989C2 |
| RARA AGONISTS FOR THE TREATMENT OF AML AND MDS | 2017 |
|
RU2799789C2 |
| COMPOSITION COMPRISING LOW-MOLECULAR FRAGMENTS OF PEPTIDOGLICANE OF GRAM-NEGATIVE BACTERIA FOR PREVENTING OR TREATING OF HUMAN DISEASES | 2009 |
|
RU2441906C2 |
| METHOD OF DETERMINING EFFICACY OF HAEMOSTIMULATORS IN CYTOSTATIC MYELOSUPPRESSION | 2009 |
|
RU2421720C2 |
| COMPOSITION AND METHOD OF REDUCING CHEMOTHERAPY-INDUCED NEUTRPENIA BY ADMINISTRATION OF PLINABULIN AND G-CSF AGENT | 2019 |
|
RU2798103C2 |
| METHOD FOR REDUCING NEUTROPENIA | 2017 |
|
RU2760348C2 |
| METHODS OF TREATING LEUKOPENIA AND THROMBOCYTOPENIA | 2015 |
|
RU2702122C2 |
| TREATING CANCER WITH IMMUNOSTIMULANTS | 2015 |
|
RU2740288C2 |
| G-CSF - CONTAINING AGENT FOR PREVENTION AND TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | 2007 |
|
RU2448726C2 |
